At the BIO International Convention in Boston, the Korean delegation was impossible to miss. Booths staffed by Korean biotech companies. Sessions featuring Korean regulatory experts. Hallway conversations in Korean between founders and American venture capitalists who had clearly done this before.
Korea has rapidly emerged as a critical player in global biotech, and the BIO Convention was the clearest evidence yet of how far that trajectory has come.
A decade ago, Korean biotech companies came to BIO as observers. Today, they come as presenters, partners, and acquirers. The shift reflects billions in Korean government investment in life sciences, a world-class clinical trial infrastructure, and a generation of Korean scientists trained at top American and European institutions who have returned home to build companies.
American VCs are paying attention. Korean biotech offers something increasingly rare in the US market: strong science at lower valuations, with a regulatory pathway through the Korean FDA that can serve as a stepping stone to US approval.
KORISE will continue covering this critical corridor between Korean innovation and global markets.